Confo Therapeutics reports grant of two key patents for ConfoBodies™ Ghent, Belgium, 2 December 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been granted two key ConfoBody™ patents derived from the patent estate known as the “Steyaert patents”. The Steyaert patents – named after Prof. Jan Steyaert (VIB-VUB), their first-named […]
Archive for the
‘2019’ Category
FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019 Ghent, Belgium, 23 September 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in […]
Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds Ghent, Belgium, and Dresden, Germany – 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). The collaboration will combine ConfoBody™-enabled GPCRs with DyNAbind’s Dynamic […]
Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication Ghent, Belgium, 20 June 2019 – Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and […]
Confo Therapeutics raises €30 million in Series A financing Round led by BioGeneration Ventures and co-led by Wellington Partners, with investments by Fund+, Perceptive Advisors and existing investors Ghent, Belgium, 7 May 2019 – Confo Therapeutics, an emerging drug discovery company, today announces the completion of a €30 million ($33.4 million) Series A financing. The […]
Confo Therapeutics forms Scientific Advisory Board as it accelerates development of proprietary drug discovery engine Ghent, Belgium, 28 February 2019 – Confo Therapeutics, an emerging drug discovery company, today announces the formation of its Scientific Advisory Board (SAB) with four key appointments: Radu Aricescu, Peter Kolb, Graeme Milligan and Jan Steyaert, Founder of Confo Therapeutics, […]
Confo Therapeutics Announces Exclusive, Worldwide License Agreement with VIB for Powerful Novel Structure Determination Technology Licence provides Confo Therapeutics with exclusive access to ‘Megabody’ Technology for High Resolution Cryo-Electron Microscopy evaluation of G-Protein Coupled Receptors, strengthening its drug discovery engine • Confo Therapeutics secures exclusive, worldwide license to new proprietary Megabody technology for GPCRs • […]